About
The Biobank of Lithuanian Population and Rare Disorders, developed by the Faculty of Medicine at Vilnius University (VU MF Biobank), is scheduled to launch in 2024, after the State Health Care Accreditation Service grants it a licence to engage in biobanking.
The VU MF Biobank will systematically collect, store and manage biospecimens of both healthy individuals and those with rare diseases from within the Lithuanian population, along with their related personal health information. Access to high-quality biospecimens and the health information of the VU MF Biobank will be available to Lithuanian and international scientists working for research and commercial organizations.
With a large number of samples from healthy individuals and individuals with rare diseases, the VU MF Biobank will promote national and international scientific cooperation and the development of personalized medicine, modern biomedical research, and the creation of new disease prevention, diagnosis, treatment and monitoring tools.
The VU MF Biobank will also conduct academic activities via participation in the study programmes of the faculty and by performing biomedical research.
Projects
Together with its partners (the National Cancer Institute, the public institution Vilnius University Hospital Santaros Klinikos, the Institute of Innovative Medicine, the Hospital of Lithuanian University of Health Sciences Kauno Klinikos and the Lithuanian University of Health Sciences), the VU MF Biobank conducts the HBRC’s (Centre for Human Biological Resources) project funded by the European Union European Regional Development Fund, Measure No. 01.1.1-CPVA-V-1 701 “Development of research, experimental development and innovation infrastructure and integration in European infrastructures” of Priority No. 1 “Promotion of research, experimental development and innovation”, Description No. 4 for project financing conditions of the Operational Programme for EU Structural Funds Investments for 2014–2020. These funds are used for the development of the VU MF Biobank infrastructure.